文献速递血栓与止血

静脉血栓栓塞症患者延长直接口服抗凝药治疗与潜在复发风险:系统综述与荟萃分析

Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2020-07-21

该系统综述与荟萃分析检索EMBASE、MEDLINE、PubMed和Cochrane对照试验中心注册库,纳入3项随机对照试验,比较静脉血栓栓塞症患者延长直接口服抗凝药治疗与非延长治疗。延长抗凝降低静脉血栓栓塞症复发(RR 0.18,95%CI 0.12至0.25)和死亡率(RR 0.39,95%CI 0.19至0.80),但增加临床相关非大出血(RR 2.51,95%CI 1.37至4.59),大出血无差异(RR 1.87,95%CI 0.19至17.85)。

要点

  • 延长直接口服抗凝药治疗降低静脉血栓栓塞症复发(RR 0.18,95%CI 0.12至0.25)和死亡率(RR 0.39,95%CI 0.19至0.80)。
  • 延长直接口服抗凝药治疗增加临床相关非大出血(RR 2.51,95%CI 1.37至4.59)。
  • 大出血无差异(RR 1.87,95%CI 0.19至17.85),但两组大出血事件数均少(直接口服抗凝药组n=9,安慰剂组n=4)。

核心结论

  • 对于持续抗凝存在临床不确定性的静脉血栓栓塞症患者,延长直接口服抗凝药治疗1年可降低静脉血栓栓塞症复发和死亡率,但可能增加临床相关非大出血事件。

研究设计与样本

  • 系统综述与荟萃分析,检索EMBASE、MEDLINE、PubMed和Cochrane对照试验中心注册库,纳入3项比较延长直接口服抗凝药治疗与非延长治疗的随机对照试验。

主要发现

  • 延长抗凝降低静脉血栓栓塞症复发(RR 0.18,95%CI 0.12至0.25)。
  • 延长抗凝降低死亡率(RR 0.39,95%CI 0.19至0.80),直接口服抗凝药组死亡n=12,安慰剂组n=18。
  • 延长抗凝增加临床相关非大出血(RR 2.51,95%CI 1.37至4.59)。
  • 大出血无差异(RR 1.87,95%CI 0.19至17.85),直接口服抗凝药组大出血n=9,安慰剂组n=4。
  • 结果主要由一项研究(AMPLIFY-EXT)驱动,评估出血结局时研究间存在显著异质性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 结果主要由一项研究(AMPLIFY-EXT)驱动。
  • 评估出血结局时研究间存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend at least 3 months of anticoagulation for venous thromboembolism (VTE). Evidence supporting indefinite anticoagulation exists in certain conditions; however, for many patients, uncertainty regarding when to discontinue anticoagulation persists. OBJECTIVE: We aimed to investigate the efficacy and safety of extended direct oral anticoagulants (DOAC) therapy in patients with VTE and clinical uncertainty regarding extended anticoagulation. METHODS: We searched EMBASE, MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials databases for randomized control trials examining extended anticoagulation with DOACs as compared to non-extended therapy for the treatment of VTE. RESULTS: Of 560 citations identified by the search, three studies were eligible. Extended anticoagulation reduced VTE recurrence (relative risk [RR] 0.18, 95% confidence interval [CI] 0.12 to 0.25), and mortality (RR 0.39, 95% CI 0.19 to 0.80) with a low total number of deaths in the DOAC group (n = 12) versus placebo (n = 18). Extended anticoagulation increased clinically relevant non-major bleedings (RR 2.51, 95% CI 1.37 to 4.59). There was no difference in rates of major bleeding (RR 1.87, 95% CI 0.19 to 17.85); however, there was a low number of major bleeding events in both DOAC (n = 9) and placebo groups (n = 4). The results were mostly driven by one study (AMPLIFY-EXT), with significant heterogeneity between studies noticed when assessing bleeding outcomes. CONCLUSION: Extended DOAC therapy for 1 year in patients with clinical uncertainty for ongoing anticoagulation can reduce VTE recurrence and mortality; however, it could increase clinically relevant non-major bleeding events.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ebraheem M, Alzahrani I, Crowther M, et al. Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32510840. doi:10.1111/jth.14949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。